TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12930237

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) group
Number of subjects: 113

Group type: COMPARATOR
Intervention: Non-VLCD group
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Completers (n = 55)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Noncompleters (n = 58)
Number of subjects: 113
Study: 10931579

Group type: EXPERIMENTAL
Intervention: MnDPDP injection (5 micromol/kg)
Number of subjects: 546
Study: 8860712

Group type: EXPERIMENTAL
Intervention: Immunoadsorption
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Heparin-induced extracorporeal LDL precipitation (HELP)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dextran sulfate adsorption
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: All procedures
Number of subjects: 19
Study: 8247815

Group type: EXPERIMENTAL
Intervention: 1/4-strength hydrogen peroxide (0.75%)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 1/2-strength hydrogen peroxide (1.5%)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 35
Study: 2951794

Group type: EXPERIMENTAL
Intervention: Fenoterol 100 micrograms and ipratropium bromide 40 micrograms per puff (2 puffs)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fenoterol 100 micrograms and ipratropium bromide 40 micrograms per puff (4 puffs)
Number of subjects: 16
Study: 29580260

Group type: EXPERIMENTAL
Intervention: Theoretically informed, participant-centred, evidence-based behaviour change interventions to improve retention in trials.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation of intervention acceptability and feasibility through focus groups.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Development of a ready-to-use evaluation framework for Studies Within A Trial.
Number of subjects: 0
Study: 27056964

Group type: EXPERIMENTAL
Intervention: Transcatheter patent foramen ovale closure plus antiplatelet therapy
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy
Number of subjects: 664

Group type: COMPARATOR
Intervention: Antiplatelet therapy alone
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Fatal or nonfatal stroke
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Fatal, life-threatening or major procedure- or device-related complications
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Fatal, life-threatening or major haemorrhagic complications
Number of subjects: 664
Study: 26149937

Group type: EXPERIMENTAL
Intervention: Simultaneous ureteroscopic lithotripsy and contralateral percutaneous nephrolithotomy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Staged ureteroscopic lithotripsy followed by staged percutaneous nephrolithotomy
Number of subjects: 103
Study: 24013574

Group type: COMPARATOR
Intervention: Dextromethorphan (DM) alone at 60 mg on day 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Panobinostat at 20 mg alone on days 3 and 5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) and panobinostat co-administered on day 8
Number of subjects: 0
Study: 20700674

Group type: EXPERIMENTAL
Intervention: Medially conforming ball-and-socket design
Number of subjects: 82

Group type: COMPARATOR
Intervention: Posterior-stabilized total knee prosthesis
Number of subjects: 82
Study: 19110787

Group type: EXPERIMENTAL
Intervention: Primary aspiration with the Export aspiration catheter followed by stenting
Number of subjects: 249

Group type: COMPARATOR
Intervention: Conventional stenting without primary aspiration
Number of subjects: 249
Study: 17227263

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 70
Study: 14584555

Group type: EXPERIMENTAL
Intervention: Patients with frontal lobe injuries
Number of subjects: 2

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Patients with injuries centered in the frontal poles
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Patients with lesions restricted to dorsolateral prefrontal cortex
Number of subjects: 2
Study: 10929919

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 125
Study: 8814419

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ) 150 mg per day for 6 months
Number of subjects: 8
Study: 1306815

Group type: EXPERIMENTAL
Intervention: Nitrendipine (active treatment group, 45 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (42 patients)
Number of subjects: 100
Study: 2867800

Group type: EXPERIMENTAL
Intervention: 30 mg thiotepa instillation at the time of primary treatment
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Instillations of thiotepa at 3‐monthly intervals for a year
Number of subjects: 417

Group type: COMPARATOR
Intervention: No instillation (Control group)
Number of subjects: 417
Study: 31213079

Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment
Number of subjects: 0
Study: 29767684

Group type: EXPERIMENTAL
Intervention: PI monotherapy
Number of subjects: 609

Group type: COMPARATOR
Intervention: Standard tritherapy
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: PI monotherapy receiving DRV/r
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Baseline USVL<1 copy/mL
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Higher baseline CD4
Number of subjects: 609
Study: 27321324

Group type: EXPERIMENTAL
Intervention: Welltang intervention group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (usual standard of care)
Number of subjects: 100
Study: 25134972

Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg BID
Number of subjects: 98

Group type: COMPARATOR
Intervention: Propafenone 150 mg TID
Number of subjects: 98
Study: 22665124

Group type: EXPERIMENTAL
Intervention: Diet containing 10% of energy from pistachios (1 serving per day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Diet containing 20% of energy from pistachios (2 servings per day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low-fat control diet (25% total fat and 8% saturated fat)
Number of subjects: 28
Study: 20447572

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 3605

Group type: EXPERIMENTAL
Intervention: Loop diuretics
Number of subjects: 3605

Group type: EXPERIMENTAL
Intervention: eGFR
Number of subjects: 3605

Group type: EXPERIMENTAL
Intervention: Higher blood pressure
Number of subjects: 3605

Group type: EXPERIMENTAL
Intervention: Lower hemoglobin levels
Number of subjects: 3605
Study: 17619081

Group type: EXPERIMENTAL
Intervention: C(18)-ceramide levels in HNSCC tumors
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: C(16)-, C(24)-, C(24:1)-ceramides levels in HNSCC tumors
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Overall stages of primary HNSCC tumors
Number of subjects: 45
Study: 17136931

Group type: EXPERIMENTAL
Intervention: Asthma education programme
Number of subjects: 639
Study: 12065927

Group type: EXPERIMENTAL
Intervention: Testosterone plus letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Testosterone plus placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study: 10527197

Group type: EXPERIMENTAL
Intervention: AngioJet F105 rheolytic catheter
Number of subjects: 153

Group type: COMPARATOR
Intervention: Surgical thrombectomy
Number of subjects: 153
Study: 8833947

Group type: EXPERIMENTAL
Intervention: Alpha-1-antitrypsin level in patients with melanoma of the choroid
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 35
Study: 1385929

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg (5 mg for patients ≤30 kg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Astemizole 2 mg/10 kg body weight
Number of subjects: 41
Study: 6502473

Group type: EXPERIMENTAL
Intervention: Antacid regimen administered for three full days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Theophylline therapy with antacids
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (theophylline therapy without antacids)
Number of subjects: 9
Study: 31674861

Group type: EXPERIMENTAL
Intervention: OMDI 0.0025% (1 drop in both eyes for 7 days)
Number of subjects: 14
Study: 30291402

Group type: EXPERIMENTAL
Intervention: Very-low-nicotine-content cigarettes (VLNCCs; 1 mg nicotine/g tobacco)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Normal-nicotine-content cigarettes (NNCCs; 16 mg/g)
Number of subjects: 118
Study: 27765120

Group type: EXPERIMENTAL
Intervention: Baseline BMI≥28.0 kg/m2
Number of subjects: 3043

Group type: EXPERIMENTAL
Intervention: Weight gains in subjects with baseline BMI<24.0 kg/m2
Number of subjects: 3043

Group type: COMPARATOR
Intervention: Stable weight (BMI change of -0.05 to +0.05 per year)
Number of subjects: 3043
Study: 24214217

Group type: EXPERIMENTAL
Intervention: sipoglitazar (8, 16, 32, or 64 mg once daily; 16 or 32 mg twice daily)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: rosiglitazone (8 mg once daily)
Number of subjects: 780

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 780
Study: 22377180

Group type: COMPARATOR
Intervention: lamotrigine
Number of subjects: 0

Group type: COMPARATOR
Intervention: gabapentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: topiramate
Number of subjects: 0
Study: 20064020

Group type: EXPERIMENTAL
Intervention: Grounding for 40 minutes
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham grounding for control session
Number of subjects: 28
Study: 17386379

Group type: COMPARATOR
Intervention: Exercise treadmill ECG (ETT)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: SPECT myocardial perfusion imaging (MPI)
Number of subjects: 457
Study: 16282930

Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate (MCC) vaccine
Number of subjects: 62
Study: 11865832

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF) 2400 mg (four 600‐mg tablets daily) for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10192613

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 8001393

Group type: EXPERIMENTAL
Intervention: Monophosphoryl lipid A (20 micrograms/kg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Monophosphoryl lipid A
Number of subjects: 44

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 44
Study: 1700873

Group type: EXPERIMENTAL
Intervention: Colloid (hydroxy ethyl starch) and electrolyte solution (group COL)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Crystalloid fluid alone (group CR)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 7019638

Group type: EXPERIMENTAL
Intervention: MAF (melphalan, adriamycin, 5‐fluorouracil)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CAF (cyclophosphamide, adriamycin, 5‐fluorouracil)
Number of subjects: 40
Study: 31873746

Group type: EXPERIMENTAL
Intervention: Cabotegravir LA 400 mg + Rilpivirine LA 600 mg IM every 4 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cabotegravir LA 600 mg + Rilpivirine LA 900 mg IM every 8 weeks
Number of subjects: 18
Study: 30869168

Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28576736

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (200,000 international units)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27382686

Group type: EXPERIMENTAL
Intervention: Pure adenoidectomy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Adenoidectomy with partial tonsillectomy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Adenoidectomy with total tonsillectomy
Number of subjects: 150

Group type: COMPARATOR
Intervention: All surgical procedures
Number of subjects: 150
Study: 25082923

Group type: EXPERIMENTAL
Intervention: Resistive inspiratory muscle training (RIMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual rehabilitation care
Number of subjects: 40
Study: 22008041

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Surveillance
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Endoscopic injection treatment
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 203
Study: 19461565

Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (lidocaine only)
Number of subjects: 60
Study: 17608965

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Sonda (LTS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: ProSeal Laryngeal Mask Airway (PLMA)
Number of subjects: 100
Study: 14999237

Group type: EXPERIMENTAL
Intervention: Self-administration of the International Prostate Symptom Score (IPSS) questionnaire.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Physician administration of the International Prostate Symptom Score (IPSS) questionnaire.
Number of subjects: 150
Study: 11260005

Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg g-1 ointment plus UVB phototherapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Vehicle plus UVB phototherapy
Number of subjects: 104
Study: 9554807

Group type: EXPERIMENTAL
Intervention: losartan, 50 mg for 14 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo for 14 days
Number of subjects: 19
Study: 7748145

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g one hour before breakfast and dinner)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 3058398

Group type: EXPERIMENTAL
Intervention: Mometasone furoate ointment (0.1 percent), applied once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mometasone furoate cream (0.1 percent), applied once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mometasone furoate ointment and cream (0.1 percent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluocinolone acetonide ointment (0.025 percent), applied three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triamcinolone acetonide ointment (0.1 percent), applied twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluocinolone acetonide cream (0.025 percent), applied three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triamcinolone acetonide cream (0.1 percent), applied twice daily
Number of subjects: 0
Study: 31680378

Group type: EXPERIMENTAL
Intervention: Eshnan (500 mg, three tablets taken orally after each meal for 2 months)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo (three tablets taken orally after each meal for 2 months)
Number of subjects: 126
Study: 29551324

Group type: EXPERIMENTAL
Intervention: Motivational outreach call, multisession telephone counseling, and assistance with obtaining nicotine replacement therapy
Number of subjects: 1938

Group type: COMPARATOR
Intervention: Usual Veterans Administration smoking services
Number of subjects: 1938
Study: 25657022

Group type: EXPERIMENTAL
Intervention: Riociguat (up to 2.5 mg three times daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Riociguat plus sildenafil
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Riociguat plus sildenafil (in long-term extension)
Number of subjects: 18
Study: 23255783

Group type: EXPERIMENTAL
Intervention: Combination of immunoglobulin A antibodies to Epstein‐Barr virus capsid antigen and nuclear antigen‐1 by enzyme‐linked immunosorbent assay and indirect mirror examination in the nasopharynx and/or lymphatic palpation (IMLP)
Number of subjects: 28688

Group type: EXPERIMENTAL
Intervention: High-risk group screening
Number of subjects: 28688

Group type: EXPERIMENTAL
Intervention: IMLP-positive group screening
Number of subjects: 28688
Study: 21602759

Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise
Number of subjects: 101

Group type: COMPARATOR
Intervention: Passive modalities
Number of subjects: 101
Study: 19551373

Group type: EXPERIMENTAL
Intervention: Oxazepam 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxazepam 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Herbal relaxant
Number of subjects: 0
Study: 16505432

Group type: EXPERIMENTAL
Intervention: TEC (carboplatin-paclitaxel-epirubicin)
Number of subjects: 1282

Group type: COMPARATOR
Intervention: TC (carboplatin-paclitaxel)
Number of subjects: 1282
Study: 12494319

Group type: EXPERIMENTAL
Intervention: Exercise training (EX)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 34
Study: 11273392

Group type: EXPERIMENTAL
Intervention: Sadness (active thought process)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Neutral mood (control group)
Number of subjects: 2
Study: 9065993

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) (n = 28)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) (n = 32)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both LMWH and UFH
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pre‐operative coagulation test results
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: D‐dimer and fibrinogen levels
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FIGO stage
Number of subjects: 60
Study: 8457132

Group type: EXPERIMENTAL
Intervention: Nifedipine (N)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prazosin (P)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acebutolol (A)
Number of subjects: 90
Study: 2873545

Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol hydrochloride
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0.6% metipranolol hydrochloride
Number of subjects: 16
Study: 30285811

Group type: EXPERIMENTAL
Intervention: Single use negative pressure wound therapy (sNPWT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: sNPWT
Number of subjects: 80
Study: 25862143

Group type: EXPERIMENTAL
Intervention: MRI group (two-core targeted biopsy guided by MRI/TRUS)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (12-core random biopsy)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: MRI group (two-core MRI/TRUS-TB)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (12-core RB)
Number of subjects: 175
Study: 24212478

Group type: EXPERIMENTAL
Intervention: 15 mg 0.5% isobaric levobupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 15 mg 0.5% isobaric bupivacaine
Number of subjects: 60
Study: 22087644

Group type: EXPERIMENTAL
Intervention: MI + CBT
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: NDC + CBT
Number of subjects: 27

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 27
Study: 20471658

Group type: EXPERIMENTAL
Intervention: Mapping between two spaces with somewhat different perceptual features
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mapping between spaces with identical features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mapping between spaces with increased differences
Number of subjects: 0
Study: 17201989

Group type: EXPERIMENTAL
Intervention: 0.5 per cent methylene blue stain
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1 per cent methylene blue stain
Number of subjects: 28
Study: 15837439

Group type: EXPERIMENTAL
Intervention: Hypothetical trial of arthroscopic partial meniscectomy
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Subjects lacking strong preferences for treatment
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Subjects with strong preferences for treatment
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 88
Study: 12067012

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10592854

Group type: EXPERIMENTAL
Intervention: Triphasic norgestimate/ethinyl estradiol (Ortho Tri‐Cyclen)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 8712120

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 480

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 480
Study: 1759004

Group type: EXPERIMENTAL
Intervention: Salbutamol aerosol 400 micrograms before and 200 micrograms 2-hourly after challenge
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral terfenadine 120 mg 2 h before and 10 h after challenge
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: No medication or antigen challenge
Number of subjects: 9
Study: 7137075

Group type: EXPERIMENTAL
Intervention: 100% lactose
Number of subjects: 8

Group type: COMPARATOR
Intervention: 50% lactose: 50% glucose polymer (lactose + glucose polymer)
Number of subjects: 8
Study: 30683533

Group type: EXPERIMENTAL
Intervention: XEN® Gel Stent as a stand-alone procedure
Number of subjects: 777

Group type: COMPARATOR
Intervention: XEN® Gel Stent in combined surgery
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: XEN® Gel Stent (both procedures)
Number of subjects: 777
Study: 28374714

Group type: EXPERIMENTAL
Intervention: Collost (medical device) in addition to standard therapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 71
Study: 26400520

Group type: EXPERIMENTAL
Intervention: 8-iso-PGF2α
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gpx
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SOD
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TBA
Number of subjects: 40
Study: 23705925

Group type: EXPERIMENTAL
Intervention: Cinacalcet + oral vitamin D (n = 33)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oral vitamin D alone (control group, n = 33)
Number of subjects: 66